Pain relief via anti-inflammatory pathways

"Pain relief via anti-inflammatory pathways" does not correspond to a single molecular target or receptor; rather, it encompasses a set of molecular mechanisms, enzymes, and receptors involved in the modulation of inflammation and nociception. Central to these pathways are enzymes such as cyclooxygenase-1 and -2, whose inhibition by NSAIDs or endogenous modulators reduces prostaglandin synthesis and inflammation; receptors such as cannabinoid receptors (CB1, CB2), which are involved in pain modulation and immune responses; and numerous signaling molecules, cytokines, and neuropeptides implicated in inflammatory pain[1][2][3][4][5][6][7]. Because "pain relief via anti-inflammatory pathways" is a description of multiple interconnected biological processes rather than an individual molecular entity, it cannot be assigned canonical target information.

Inhibition of cyclooxygenase (COX-1, COX-2) to block prostaglandin synthesis[1][3][5][7] - Inhibition/modulation of inflammatory cytokine signaling (e.g., TNF-α, IL-1β)[3] - Modulation of endocannabinoid system (CB1/CB2 receptors)[1][2][6] - Modulation of neurotrophic and inflammatory mediator pathways (NF-κB, MAPK, AMPK)[2][3][4]